Результаты поиска

Воздействие онлайновой программы поддержки пациентов под руководством медсестер на усталость, сон и качество жизни у пациентов с множественным склерозом: квазиэкспериментальное исследование.

Множественный склероз (MS) становится все более распространенным. Физические расстройства и проблемы со сном, особенно усталость, ухудшают качество жизни этих пациентов. One Одним из наиболее успешных и долгосрочных стратегий борьбы с симптомами является обучение пациентов. Цель этого исследования заключалась в оценке воздействия онлайновой программы поддержки под руководством медсестер на усталость, сон и качество жизни пациентов с множественным склерозом (PwMS). МЕТОДЫ: Это квазиэкспериментальное исследование было проведено в амбулаторной клинике MS одной из университетских больниц в Стамбул

Совпадение в полном тексте источника
… A further objective was to explore the clinical significance of changes by comparing observed effects with minimal clinically important difference (MCID) thresholds. Feasibility outcomes (e.g., dropout rate, adherence) were also monitored to assess acceptability of the intervention. … clinically important difference (MCID) for FSS, 66.7% of participants experienced a meaningful reduction in fatigue following the intervention.  …

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).

Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the promise of improving patients' health-related quality of life (HRQoL). Within this rapidly evolving landscape, the inclusion of HRQoL and other patient-reported outcomes (PROs) is critical to inform the benefit/risk assessment of new therapies or to assess whether patients live longer and better, for what will likely remain a largely incurable disease. We provide

Uncommon Factors Leading to Nephrotic Syndrome.

Nephrotic syndrome (NS) is characterized by proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Apart from the traditional causes of NS, such as minimal change disease, focal segmental glomerulosclerosis, diabetes, infections, malignancies, autoimmune conditions, and nephrotoxic agents, there are also rare causes of NS, whose knowledge is of the utmost importance. The aim of this article was to highlight the less well-known causes that have a significant impact on diagnosis and treatment. Genetic syndromes such as Schimke immuno-osseous dysplasia, familial lecithin-cholesterol acyltransfe

Ixazomib, Lenalidomide и Dexamethasone (IRD) Лечение с цитогенетическим обслуживанием на основе риска в Трансплантационной миеломе: фазы 2 Мультицентральное исследование, проведенное Исследовательской группой Северной Европы по миеломе.

Имеются скудные данные о двойном обслуживании недавно диагностированных пациентов с высокой степенью риска при пересадке (РЧ) с несколькими миеломой (НДММ). Это будущее фазы 2 зачисленные в учебные заведения 120 Пациенты NDMM, отвечающие требованиям трансплантации. Лечение состояло из: four Циклы впрыскивания ixazomib-lenalidomide-dexamethason (IRD) плюс аутологическая трансплантация стволовых клеток, за которыми следуют консолидация IRD и цитогенетическая психотерапия на основе цитогенетического риска с использованием линалидомида + ixazomib (IR) только для пациентов HR и линалидомида (R) для

Nanomaterial-Driven Precision Immunomodulation: A New Paradigm in Therapeutic Interventions.

Immunotherapy is a rapidly advancing field of research in the treatment of conditions such as cancer and autoimmunity. Nanomaterials can be designed for immune system manipulation, with precise targeted delivery and improved immunomodulatory efficacy. Here, we elaborate on various strategies using nanomaterials, including liposomes, polymers, and inorganic NPs, and discuss their detailed design intricacies, mechanisms, and applications, including the current regulatory issues. This type of nanomaterial design for targeting specific immune cells or tissues and controlling release kinetics could

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma.

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, largely because frailty complicates treatment decisions and frequently leads to the exclusion of frail patients from pivotal clinical trials. Recent subgroup analyses provide useful insight into whether quadruplet therapy may offer advantages over triplet therapy in this population. Data from the IMROZ and CEPHEUS trials were reviewed to compare outcomes between quadruplet and triplet regimens in both the overall intent-to-treat cohorts and the frailty-defined subgroups. Frailty was assessed using the

A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy.

Clinical trials of cancer immunotherapy (IO) were historically based on a drug development paradigm built for chemotherapies. The remarkable clinical activity of programmed cell death protein 1/programmed death ligand 1 blockade, chimeric antigen receptor-T cells, and T cell engagers yielded new insights into how the mechanistic underpinnings of IO are reflected in the clinic. These insights and the sheer number of novel immunotherapies currently in the pipeline have made it clear that our strategies and tools for IO drug development must adapt. Recent innovations like engineered T cells and t

An Updated Comprehensive Review on Diseases Associated with Nephrotic Syndromes.

There have been exciting advances in our knowledge of primary glomerular diseases and nephrotic syndromes in recent years. Beyond the histological pattern from renal biopsy, more precise phenotyping of the diseases and the use of modern nephrogenetics helps to improve treatment decisions and sometimes also avoid unnecessary exposure to potentially toxic immunosuppression. New biomarkers have led to easier and more accurate diagnoses and more targeted therapeutic decisions. The treatment landscape is becoming wider with a pipeline of promising new therapeutic agents with more sophisticated appr

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.

Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment

Mid-term outcomes for Endoscopic versus Open Vein Harvest: a case control study.

BackgroundSaphenous vein remains the most common conduit for coronary artery bypass grafting with increasing uptake of minimally invasive harvesting techniques. While Endoscopic Vein Harvest (EVH) has been demonstrated to improve early morbidity compared to Open Vein Harvest (OVH), recent literature suggests that this may be at the expense of graft patency at one year and survival at three years.MethodsWe undertook a retrospective single-centre, single-surgeon, case-control study of EVH (n = 89) and OVH (n = 182). The primary endpoint was death with secondary endpoints including acute coronary

Refining risk prediction in pediatric acute lymphoblastic leukemia through DNA methylation profiling.

Acute lymphoblastic leukemia (ALL) is the most prevalent cancer in children, and despite considerable progress in treatment outcomes, relapses still pose significant risks of mortality and long-term complications. To address this challenge, we employed a supervised machine learning technique, specifically random survival forests, to predict the risk of relapse and mortality using array-based DNA methylation data from a cohort of 763 pediatric ALL patients treated in Nordic countries. The relapse risk predictor (RRP) was constructed based on 16 CpG sites, demonstrating c-indexes of 0.667 and 0.

Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Систематический обзор и метаанализ выборочных контролируемых испытаний этапа III для оценки риска пневмонии, УРТИ и ВТЕ у нескольких пациентов миеломы, проходящих лечение изатуксимабом.

Множественная миелома (ММ) — гематологическая порча, характеризующаяся клональным распространением злокачественных плазменных клеток в костном мозге, составляющих приблизительно 13% из всех гематологических магнатов. Isatuximab — моноколональное антитело, направленное против белка CD38 на клетках миэломы, приводящее к смерти клеток с помощью различных иммунных средств. Клинические испытания показали, что добавление изатуксимаба в стандартные режимы для MM значительно повышает эффективность, но приводит к некоторым заметным токсичным явлениям. Цель этого исследования состоит в том, чтобы опреде

Therapeutic education and physical activity are feasible and safe in hematologic cancer patients referred to chemotherapy: results of a randomized controlled trial.

PurposeAlthough over 60% of patients with hematologic cancer report distressing fatigue, they often do not receive recommendations on fatigue management strategies. The aim of this pilot study was to estimate the feasibility of therapeutic education and physical activity (TEPA) by measuring the patients' adherence to this multidimensional intervention. The secondary aim was to estimate the impact of TEPA on clinical outcomes.MethodsPatients with hematologic cancer participated in this single-center, open-label, randomized controlled trial. The control group (CG) received two educational group

Совпадение в полном тексте источника
… Of note, the improvement achieved by participants in the EG in CRF was clinically relevant, as the mean change from T0 to follow-up exceeded the cutoff of minimal clinically important difference set for the FACIT-F [ 25 ]. … For all the other outcome measures used, the cutoffs of minimal clinically important difference have not been established in hematologic patients. Some considerations must be made to better interpret these results. …

Влияние возраста на изменение или прекращение болезней, изменяющих терапию при множественном склерозе.

Пожилые пациенты в возрасте ≥55 лет составляют почти половину от общей численности населения страны. Несмотря на то, что в результате возникновения заболеваний происходят такие точечные и подстрекательские процессы демиелионации и такие прогрессивные процессы, как разрозненное воспаление CNS, нейродегенерация и отказ компенсационных механизмов, наблюдается сдвиг в преобладающих болезнях с заметным клиническим прогрессом в течение пятого десятилетия жизни. Клинически это проявляется в уменьшении числа рецидивов в клинической области и активности МРТ в качестве лиц в возрасте MS, что приводит к

Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology.

Technological advancements in cell-free DNA (cfDNA) liquid biopsy have triggered exponential growth in numerous clinical applications. While cfDNA-based liquid biopsy has made significant strides in personalizing cancer treatment, the exploration and translation of epigenetics in liquid biopsy to clinical practice is still nascent. This comprehensive review seeks to provide a broad yet in-depth narrative of the present status of epigenetics in cfDNA liquid biopsy and its associated challenges. It highlights the potential of epigenetics in cfDNA liquid biopsy technologies with the hopes of enha

Oral Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Full-text articles, whose primary purpose was to evaluate the psychometric properties or minimal clinically important differences (MCID) of DCM assessment tools, were included. … In the NBP group, 13% reported clinically significant back pain (NRS difference greater than Minimally Clinical Important Difference (MICD)) at the one-year follow-up. …

:: 8th Европейский конгресс фармацевтики: выдержки из выступлений

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Kyphoplasty for Elderly Patients With Vertebral Compression Fractures-Do We Save Lives? Mortality Rates Analysis Comparison in a Long-Term Follow-Up Cohort.

Study designRetrospective cohort.ObjectivesWe aimed to compare a large cohort of patients with vertebral compression fractures (VCF) treated in 2 centers using different protocols (conservative vs BKP) and compare mortality rates on a long-term follow-up.MethodsRetrospective cohort held in 2 medical centers (W and AH). All patients admitted with VCF from November 2008 to January 2015 were enrolled in the study. Exclusion criteria were patients admitted with non-osteoporotic pathological fractures (such as metastatic or MM).ResultsOur study included 208 patients treated for VCF, 127 were treate

Baseline Characteristics of Individuals with Metastatic Cancer Enrolled in the Alberta Cancer Exercise Study and 12-Week Findings for Symptom-Related and Physical Fitness Measures.

Exercise has been found to be safe and beneficial for people with advanced cancers, but more research is needed to understand how best to design and implement exercise programming. The Alberta Cancer Exercise (ACE) study examines the effectiveness and implementation of a 12-week community-based exercise program in Alberta, Canada, for people diagnosed with cancer. Here, we describe the characteristics of individuals with metastatic cancer enrolled in the ACE program and report 12-week changes in self-reported and objective outcomes. Of 306 participants, 274 (89.5%) completed the 12-week study.

Совпадение в полном тексте источника
… Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study. Cancer. 2015;121:3027–3035. doi: 10.1002/cncr.29437. 49. … Minimal clinically important difference in the physical, emotional, and total symptom distress scores of the Edmonton Symptom Assessment System. J. Pain Symptom Manag. 2016;51:262–269. doi: 10.1016/j.jpainsymman.2015.10.004. 50. …